Literature DB >> 30891866

Timing of combination antiretroviral therapy (cART) initiation is not associated with stillbirth among HIV-infected pregnant women in Malawi.

Malango T Msukwa1,2, Olivia Keiser1, Andreas Jahn3, Joep J van Oosterhout4,5, Andrew Edmonds6, Nozgechi Phiri1,2, Ronald Manjomo2, Mary-Ann Davies7, Janne Estill1,8.   

Abstract

OBJECTIVE: To assess the association between timing of maternal combination ART (cART) initiation and stillbirth among HIV-infected pregnant women in Malawi's Option B+ programme.
METHODS: Cohort study of HIV-infected pregnant women delivering singleton live or stillborn babies at ≥28 weeks of gestation using routine data from maternity registers between 1 January 2012 and 30 June 2015. We defined stillbirth as death of a foetus at ≥28 weeks of gestation. We report proportions of stillbirth according to timing of maternal cART initiation (before pregnancy, 1st or 2nd trimester, or 3rd trimester or labour). We used logistic regression, with robust standard errors to account for clustering of women within health facilities, to investigate the association between timing of cART initiation and stillbirth.
RESULTS: Of 10 558 mother-infant pairs abstracted from registers, 8380 (79.4%) met inclusion criteria. The overall rate of stillbirth was 25 per 1000 deliveries (95% confidence interval 22-29). We found no significant association between timing of maternal cART initiation and stillbirth. In multivariable models, older maternal age, male sex of the infant, breech vaginal delivery, delivery at < 34 weeks of gestation and experience of any maternal obstetric complication were associated with higher odds of stillbirth. Deliveries managed by a mission hospital or health centre were associated with lower odds of stillbirth.
CONCLUSION: Pregnant women's exposure to cART, regardless of time of its initiation, was not associated with increased odds of stillbirth.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HIVzzm321990; zzm321990VIHzzm321990; Malawi; Option B+; combination antiretroviral therapy; mortinaissance; option B+; stillbirth; traitement de combinaison d'antirétroviraux

Mesh:

Substances:

Year:  2019        PMID: 30891866      PMCID: PMC7137352          DOI: 10.1111/tmi.13233

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  34 in total

Review 1.  The infectious origins of stillbirth.

Authors:  Robert L Goldenberg; Cortney Thompson
Journal:  Am J Obstet Gynecol       Date:  2003-09       Impact factor: 8.661

Review 2.  The risks of planned vaginal breech delivery versus planned caesarean section for term breech birth: a meta-analysis including observational studies.

Authors:  Y Berhan; A Haileamlak
Journal:  BJOG       Date:  2015-07-29       Impact factor: 6.531

3.  Antiretrovirals causing severe pre-eclampsia.

Authors:  Lloyd Tooke; Linda Riemer; Mushi Matjila; Michael Harrison
Journal:  Pregnancy Hypertens       Date:  2016-04-26       Impact factor: 2.899

4.  Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.

Authors:  Catherine A Koss; Paul Natureeba; Julia Mwesigwa; Deborah Cohan; Bridget Nzarubara; Peter Bacchetti; Howard Horng; Tamara D Clark; Albert Plenty; Theodore D Ruel; Jane Achan; Edwin D Charlebois; Moses R Kamya; Diane V Havlir; Monica Gandhi
Journal:  AIDS       Date:  2015-04-24       Impact factor: 4.177

5.  Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception.

Authors:  E S Machado; C B Hofer; T T Costa; S A Nogueira; R H Oliveira; T F Abreu; L A Evangelista; I F A Farias; R T C Mercadante; M F L Garcia; R C Neves; V M Costa; J S Lambert
Journal:  Sex Transm Infect       Date:  2008-11-05       Impact factor: 3.519

6.  Predictors of stillbirth in sub-saharan Africa.

Authors:  Benjamin H Chi; Lei Wang; Jennifer S Read; Taha E Taha; Moses Sinkala; Elizabeth R Brown; Megan Valentine; Francis Martinson; Robert L Goldenberg
Journal:  Obstet Gynecol       Date:  2007-11       Impact factor: 7.661

7.  Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study.

Authors:  Andreas D Haas; Lyson Tenthani; Malango T Msukwa; Kali Tal; Andreas Jahn; Oliver J Gadabu; Adrian Spoerri; Frank Chimbwandira; Joep J van Oosterhout; Olivia Keiser
Journal:  Lancet HIV       Date:  2016-03-09       Impact factor: 12.767

8.  Weight gain of HIV-exposed, uninfected children born before and after introduction of the 'Option B+' programme in Malawi.

Authors:  Malango T Msukwa; Janne Estill; Andreas D Haas; Joep J van Oosterhout; Lyson Tenthani; Mary-Ann Davies; Kali Tal; Nozgechi Phiri; Adrian Spoerri; Bryan C Mthiko; Frank Chimbwandira; Olivia Keiser
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

9.  Option B+ for prevention of vertical HIV transmission has no influence on adverse birth outcomes in a cross-sectional cohort in Western Uganda.

Authors:  Eva M Rempis; Alexandra Schnack; Sarah Decker; Vera Braun; John Rubaihayo; Nazarius Mbona Tumwesigye; Priscilla Busingye; Gundel Harms; Stefanie Theuring
Journal:  BMC Pregnancy Childbirth       Date:  2017-03-07       Impact factor: 3.007

Review 10.  Stillbirths: rates, risk factors, and acceleration towards 2030.

Authors:  Joy E Lawn; Hannah Blencowe; Peter Waiswa; Agbessi Amouzou; Colin Mathers; Dan Hogan; Vicki Flenady; J Frederik Frøen; Zeshan U Qureshi; Claire Calderwood; Suhail Shiekh; Fiorella Bianchi Jassir; Danzhen You; Elizabeth M McClure; Matthews Mathai; Simon Cousens
Journal:  Lancet       Date:  2016-01-19       Impact factor: 79.321

View more
  4 in total

1.  Behavioral Interventions can Mitigate Adverse Pregnancy Outcomes Among Women Conceiving on ART and Those Initiated on ART During Pregnancy: Findings From the MOTIVATE Trial in Southwestern Kenya.

Authors:  Maricianah Onono; Tobias Odwar; Samuel Wahome; Anna Helova; Elizabeth Anne Bukusi; Karen Hampanda; Janet Turan; Lisa Abuogi
Journal:  J Acquir Immune Defic Syndr       Date:  2021-01-01       Impact factor: 3.771

2.  Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women.

Authors:  Vincent J Tukei; Heather J Hoffman; Lauren Greenberg; Ramatlapeng Thabelo; Masepeli Nchephe; Tsietso Mots'oane; Matseliso Masitha; Mammatli Chabela; Majoalane Mokone; Lynne Mofenson; Laura Guay; Appolinaire Tiam
Journal:  Pediatr Infect Dis J       Date:  2021-09-01       Impact factor: 3.806

3.  Pregnancy and Birth Outcomes Among Women on Antiretroviral Therapy: A Long-term Retrospective Analysis of Data from a Major Tertiary Hospital in North Central Nigeria.

Authors:  Maxwell P Dapar; Benjamin N Joseph; Rotkangmwa C Okunlola; Josiah Mutihir; Moses P Chingle; Mathilda E Banwat
Journal:  Int J MCH AIDS       Date:  2021-10-28

4.  Differential impact of antiretroviral therapy initiated before or during pregnancy on placenta pathology in HIV-positive women.

Authors:  Nadia M Ikumi; Thokozile R Malaba; Komala Pillay; Marta C Cohen; Hlengiwe P Madlala; Mushi Matjila; Dilly Anumba; Landon Myer; Marie-Louise Newell; Clive M Gray
Journal:  AIDS       Date:  2021-04-01       Impact factor: 4.177

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.